1. Home
  2. BLKB vs URGN Comparison

BLKB vs URGN Comparison

Compare BLKB & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blackbaud Inc.

BLKB

Blackbaud Inc.

HOLD

Current Price

$31.09

Market Cap

1.5B

Sector

Technology

ML Signal

HOLD

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

HOLD

Current Price

$30.05

Market Cap

1.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLKB
URGN
Founded
1981
2004
Country
United States
United States
Employees
2800
291
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.5B
1.4B
IPO Year
2004
2016

Fundamental Metrics

Financial Performance
Metric
BLKB
URGN
Price
$31.09
$30.05
Analyst Decision
Hold
Strong Buy
Analyst Count
3
7
Target Price
$50.00
$29.29
AVG Volume (30 Days)
585.7K
906.5K
Earning Date
04-29-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
142.32
N/A
EPS
0.67
N/A
Revenue
N/A
$1,128,000.00
Revenue This Year
$6.26
$129.09
Revenue Next Year
$4.25
$70.96
P/E Ratio
$46.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$30.60
$3.61
52 Week High
$74.86
$32.37

Technical Indicators

Market Signals
Indicator
BLKB
URGN
Relative Strength Index (RSI) 33.37 65.50
Support Level N/A $17.86
Resistance Level $40.38 $32.37
Average True Range (ATR) 1.96 2.00
MACD -0.35 0.05
Stochastic Oscillator 13.39 76.17

Price Performance

Historical Comparison
BLKB
URGN

About BLKB Blackbaud Inc.

Founded in 1981, Blackbaud provides software solutions designed to serve the "social good" community, including nonprofits, foundations, corporations, educational institutions, healthcare institutions, and individual change agents. Through M&A and organic product development efforts, the company has also moved into related areas outside core fundraising, notably into K-12 schools. The firm enables more than $100 billion in donations annually across a customer base in excess of 40,000 customers in over 100 countries.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. The company's flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with Zusduri (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. The revenue source for the company comes from sales of the Company's approved products, Jelmyto and Zusduri, principally conducted in the United States.

Share on Social Networks: